NZ543367A - Plasminogen activating factors from DSPA for the treatment of stroke at a dosage of 62.5 to 230 micrograms/kg - Google Patents

Plasminogen activating factors from DSPA for the treatment of stroke at a dosage of 62.5 to 230 micrograms/kg

Info

Publication number
NZ543367A
NZ543367A NZ543367A NZ54336704A NZ543367A NZ 543367 A NZ543367 A NZ 543367A NZ 543367 A NZ543367 A NZ 543367A NZ 54336704 A NZ54336704 A NZ 54336704A NZ 543367 A NZ543367 A NZ 543367A
Authority
NZ
New Zealand
Prior art keywords
stroke
dspa
use according
acceptable salt
plasminogen
Prior art date
Application number
NZ543367A
Other languages
English (en)
Inventor
Wolfgang Sohngen
Wolf-Dieter Schleuning
Robert Medcalf
Mariola Sohngen
Original Assignee
Paion Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2003/004729 external-priority patent/WO2004096267A1/de
Application filed by Paion Deutschland Gmbh filed Critical Paion Deutschland Gmbh
Publication of NZ543367A publication Critical patent/NZ543367A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ543367A 2003-05-02 2004-04-30 Plasminogen activating factors from DSPA for the treatment of stroke at a dosage of 62.5 to 230 micrograms/kg NZ543367A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP03/04608 2003-05-02
PCT/EP2003/004729 WO2004096267A1 (de) 2003-05-02 2003-05-06 Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall
PCT/EP2004/004626 WO2004096268A2 (de) 2003-05-02 2004-04-30 Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall

Publications (1)

Publication Number Publication Date
NZ543367A true NZ543367A (en) 2010-06-25

Family

ID=35610451

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ543367A NZ543367A (en) 2003-05-02 2004-04-30 Plasminogen activating factors from DSPA for the treatment of stroke at a dosage of 62.5 to 230 micrograms/kg

Country Status (10)

Country Link
EP (1) EP1622639B1 (enExample)
JP (1) JP2006525270A (enExample)
KR (1) KR101212631B1 (enExample)
BR (1) BRPI0409865A (enExample)
CA (1) CA2524573A1 (enExample)
HR (1) HRP20050903B1 (enExample)
NO (1) NO337485B1 (enExample)
NZ (1) NZ543367A (enExample)
PL (1) PL1622639T3 (enExample)
WO (1) WO2004096268A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
DE10342518A1 (de) * 2003-09-12 2005-05-12 Paion Gmbh Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
EA017982B1 (ru) 2005-02-24 2013-04-30 ДИФФЬЮЖН ФАРМАСЬЮТИКАЛЗ ЭлЭлСи Фармацевтическая композиция на основе транскаротиноидов и способы лечения опухоли
EP1897554A1 (en) * 2006-08-25 2008-03-12 PAION Deutschland GmbH Method for the manufacture of a medicament for treating hemorrhagic stroke
WO2008022801A1 (en) * 2006-08-25 2008-02-28 Paion Deutschland Gmbh Method for the manufacture of a medicament for treating hemorrhagic stroke
BRPI0810647A2 (pt) 2007-04-13 2014-11-04 Diffusion Pharmaceuticals Llc " uso de trans carotenóides bipolares como um pré-tratamento e no tratamento de doença vascular periférica ".
DK2440230T3 (da) 2009-06-10 2021-01-18 Nono Inc Behandlingsregimener til behandling af neurologisk sygdom
EP3539542B1 (en) 2009-06-22 2023-04-19 Diffusion Pharmaceuticals LLC Diffusion enhancing compounds and their use with a thrombolytic
US8652476B2 (en) 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
JP5823671B2 (ja) * 2009-07-27 2015-11-25 国立大学法人 新潟大学 免疫製剤を含む脳梗塞治療用医薬品組成物
JP5823672B2 (ja) * 2009-07-27 2015-11-25 国立大学法人 新潟大学 受容体シグナル伝達阻害剤を含む脳梗塞治療用医薬品組成物
ES2654945T3 (es) 2010-06-02 2018-02-15 Diffusion Pharmaceuticals Llc Formulaciones orales de carotenoides trans bipolares
AU2012274910B2 (en) 2011-06-24 2017-05-11 Nono, Inc. Combination therapy with PSD-95 inhibitor for ischemia
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
EP3432929A4 (en) 2016-03-24 2019-11-27 Diffusion Pharmaceuticals LLC USE OF BIPOLAR TRANSCAROTINOIDS WITH CHEMOTHERAPY AND RADIOTHERAPY FOR THE TREATMENT OF CANCER
US10617756B2 (en) 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK176140B1 (da) * 1988-07-20 2006-09-25 Schering Ag Patentabteilung Flagermusspyt-plasminogenaktivatorer
NL8902454A (nl) * 1989-10-03 1991-05-01 Stichting Centraal Lab Mutanten van de humane plasminogeen activator inhibitor 1 (pai-1), hun bereiding en toepassing, en recombinante polynucleotiden die voor deze mutanten coderende genetische informatie omvatten.
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall

Also Published As

Publication number Publication date
KR101212631B1 (ko) 2012-12-14
EP1622639B1 (de) 2013-01-16
NO20055692D0 (no) 2005-12-01
EP1622639A2 (de) 2006-02-08
BRPI0409865A (pt) 2006-05-16
HRP20050903B1 (hr) 2013-11-22
PL1622639T3 (pl) 2013-06-28
HRP20050903A2 (en) 2006-08-31
WO2004096268A2 (de) 2004-11-11
KR20060020616A (ko) 2006-03-06
CA2524573A1 (en) 2004-11-11
WO2004096268A3 (de) 2005-04-21
NO337485B1 (no) 2016-04-25
NO20055692L (no) 2006-01-30
JP2006525270A (ja) 2006-11-09

Similar Documents

Publication Publication Date Title
US8071091B2 (en) Non-neurotoxic plasminogen activating factors for treating stroke
KR101212631B1 (ko) 뇌졸중을 치료하기 위한 플라스미노겐 비-신경독성활성인자의 정맥내 주사 방법
JP2006525270A5 (enExample)
AU2010200718A1 (en) Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
US20080057050A1 (en) Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
US20060135425A1 (en) Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
AU2008201735A1 (en) Non-neurotoxic plasminogen activating factors for treating stroke
HK1092045B (en) Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
MXPA05011761A (en) Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
HK1057328B (en) Non-neurotoxic plasminogen activating factors for treating stroke

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: H. LUNDBECK A/S, DK

Free format text: OLD OWNER(S): PAION DEUTSCHLAND GMBH

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 APR 2017 BY CPA GLOBAL

Effective date: 20140313

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 30 APR 2024 BY CPA GLOBAL

Effective date: 20140906

EXPY Patent expired